Feedback

Characterization of Potent ABCG2 Inhibitor Derived from Chromone: From the Mechanism of Inhibition to Human Extracellular Vesicles for Drug Delivery

ORCID
0000-0003-1882-1512
Affiliation
Graduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Valdameri, Glaucio;
Affiliation
Graduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Kita, Diogo Henrique;
Affiliation
Graduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Dutra, Julia de Paula;
Affiliation
Graduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Gomes, Diego Lima;
ORCID
0000-0001-6986-4198
Affiliation
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland
Tonduru, Arun Kumar;
ORCID
0000-0001-6933-7590
Affiliation
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland
Kronenberger, Thales;
Affiliation
Microbiology, Parasitology and Pathology Program, Federal University of Parana, Curitiba 81530-000, PR, Brazil
Gavinho, Bruno;
ORCID
0000-0001-5495-8167
Affiliation
Cell and Molecular Biology Program, Federal University of Parana, Curitiba 81530-000, PR, Brazil
Rossi, Izadora Volpato;
Affiliation
Biopol, Graduate Program in Pharmaceutical Sciences, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Carvalho, Mariana Mazetto de;
Affiliation
Département de Pharmacochimie Moléculaire UMR 5063, Université Grenoble Alpes, 38041 Grenoble, France
Pérès, Basile;
Affiliation
Graduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Zattoni, Ingrid Fatima;
Affiliation
Graduate Program in Pharmaceutical Sciences, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Rego, Fabiane Gomes de Moraes;
Affiliation
Graduate Program in Pharmaceutical Sciences, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Picheth, Geraldo;
Affiliation
Biopol, Graduate Program in Pharmaceutical Sciences, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Freitas, Rilton Alves de;
ORCID
0000-0003-4196-4204
Affiliation
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland
Poso, Antti;
ORCID
0000-0002-2639-4955
Affiliation
Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4256, USA
Ambudkar, Suresh V.;
Affiliation
Laboratory of Cell Biology, Carlos Chagas Institute, Fiocruz, Curitiba 81310-020, PR, Brazil
Ramirez, Marcel I.;
ORCID
0000-0002-1830-6409
Affiliation
Université Grenoble Alpes, INSERM, LRB, 38000 Grenoble, France
Boumendjel, Ahcène;
Affiliation
Graduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba 80210-170, PR, Brazil
Moure, Vivian Rotuno

Inhibition of ABC transporters is a promising approach to overcome multidrug resistance in cancer. Herein, we report the characterization of a potent ABCG2 inhibitor, namely, chromone 4a ( C4a ). Molecular docking and in vitro assays using ABCG2 and P-glycoprotein (P-gp) expressing membrane vesicles of insect cells revealed that C4a interacts with both transporters, while showing selectivity toward ABCG2 using cell-based transport assays. C4a inhibited the ABCG2-mediated efflux of different substrates and molecular dynamic simulations demonstrated that C4a binds in the Ko143-binding pocket. Liposomes and extracellular vesicles (EVs) of Giardia intestinalis and human blood were used to successfully bypass the poor water solubility and delivery of C4a as assessed by inhibition of the ABCG2 function. Human blood EVs also promoted delivery of the well-known P-gp inhibitor, elacridar. Here, for the first time, we demonstrated the potential use of plasma circulating EVs for drug delivery of hydrophobic drugs targeting membrane proteins.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: © 2023 by the authors.

Use and reproduction: